U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Unresectable Bladder Urothelial Carcinoma

MedGen UID:
1682786
•Concept ID:
C4764278
•
Neoplastic Process

Definition

Bladder urothelial carcinoma that is not amenable to surgical resection. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVUnresectable Bladder Urothelial Carcinoma

Professional guidelines

PubMed

Emerging monoclonal antibody therapies in the treatment of metastatic urothelial carcinoma.
Jain RK, Singh AM, Wang X, Guevara-Patiño JA, Sonpavde G
Expert Opin Emerg Drugs 2023 Mar;28(1):17-26. Epub 2023 Mar 7 doi: 10.1080/14728214.2023.2186398. PMID: 36882977
An evaluation of the efficacy and safety of erdafitinib for the treatment of bladder cancer.
Nauseef JT, Villamar DM, Lebenthal J, Vlachostergios PJ, Tagawa ST
Expert Opin Pharmacother 2020 Jun;21(8):863-870. Epub 2020 Mar 3 doi: 10.1080/14656566.2020.1736036. PMID: 32124650
Management of metastatic bladder cancer.
Nadal R, Bellmunt J
Cancer Treat Rev 2019 Jun;76:10-21. Epub 2019 Apr 15 doi: 10.1016/j.ctrv.2019.04.002. PMID: 31030123

Recent clinical studies

Etiology

Nivolumab plus Gemcitabine-Cisplatin in Advanced Urothelial Carcinoma.
van der Heijden MS, Sonpavde G, Powles T, Necchi A, Burotto M, Schenker M, Sade JP, Bamias A, Beuzeboc P, Bedke J, Oldenburg J, Chatta G, Ürün Y, Ye D, He Z, Valderrama BP, Ku JH, Tomita Y, Filian J, Wang L, Purcea D, Patel MY, Nasroulah F, Galsky MD; CheckMate 901 Trial Investigators
N Engl J Med 2023 Nov 9;389(19):1778-1789. Epub 2023 Oct 22 doi: 10.1056/NEJMoa2309863. PMID: 37870949
Avelumab First-line Maintenance Therapy for Advanced Urothelial Carcinoma: Comprehensive Clinical Subgroup Analyses from the JAVELIN Bladder 100 Phase 3 Trial.
Grivas P, Park SH, Voog E, Caserta C, Gurney H, Bellmunt J, Kalofonos H, Ullén A, Loriot Y, Sridhar SS, Yamamoto Y, Petrylak DP, Sternberg CN, Gupta S, Huang B, Costa N, Laliberte RJ, di Pietro A, Valderrama BP, Powles T
Eur Urol 2023 Jul;84(1):95-108. Epub 2023 Apr 28 doi: 10.1016/j.eururo.2023.03.030. PMID: 37121850
Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study.
Siefker-Radtke AO, Necchi A, Park SH, García-Donas J, Huddart RA, Burgess EF, Fleming MT, Rezazadeh Kalebasty A, Mellado B, Varlamov S, Joshi M, Duran I, Tagawa ST, Zakharia Y, Akapame S, Santiago-Walker AE, Monga M, O'Hagan A, Loriot Y; BLC2001 Study Group
Lancet Oncol 2022 Feb;23(2):248-258. Epub 2022 Jan 11 doi: 10.1016/S1470-2045(21)00660-4. PMID: 35030333
Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial.
Powles T, Csőszi T, Özgüroğlu M, Matsubara N, Géczi L, Cheng SY, Fradet Y, Oudard S, Vulsteke C, Morales Barrera R, Fléchon A, Gunduz S, Loriot Y, Rodriguez-Vida A, Mamtani R, Yu EY, Nam K, Imai K, Homet Moreno B, Alva A; KEYNOTE-361 Investigators
Lancet Oncol 2021 Jul;22(7):931-945. Epub 2021 May 26 doi: 10.1016/S1470-2045(21)00152-2. PMID: 34051178
Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma.
Powles T, Park SH, Voog E, Caserta C, Valderrama BP, Gurney H, Kalofonos H, Radulović S, Demey W, Ullén A, Loriot Y, Sridhar SS, Tsuchiya N, Kopyltsov E, Sternberg CN, Bellmunt J, Aragon-Ching JB, Petrylak DP, Laliberte R, Wang J, Huang B, Davis C, Fowst C, Costa N, Blake-Haskins JA, di Pietro A, Grivas P
N Engl J Med 2020 Sep 24;383(13):1218-1230. Epub 2020 Sep 18 doi: 10.1056/NEJMoa2002788. PMID: 32945632

Diagnosis

Real-world outcomes of first-line chemotherapy for unresectable stage III and IV bladder cancer.
Reesink DJ, van Melick HHE, van der Nat PB, Los M, Horenblas S, van de Garde EMW; Santeon MIBC Study Group
World J Urol 2023 Jun;41(6):1551-1562. Epub 2023 May 5 doi: 10.1007/s00345-023-04408-w. PMID: 37145158
Switch-maintenance avelumab immunotherapy following first-line chemotherapy for patients with advanced, unresectable or metastatic urothelial carcinoma: the first Japanese real-world evidence from a multicenter study.
Miyake M, Shimizu T, Oda Y, Tachibana A, Ohmori C, Itami Y, Kiba K, Tomioka A, Yamamoto H, Ohnishi K, Nishimura N, Hori S, Morizawa Y, Gotoh D, Nakai Y, Torimoto K, Fujii T, Tanaka N, Fujimoto K
Jpn J Clin Oncol 2023 Mar 7;53(3):253-262. doi: 10.1093/jjco/hyac186. PMID: 36484294
Reasons for lack of treatment in patients with locally advanced, unresectable or metastatic urothelial carcinoma.
Omland LH, Joensen UN, Toft BG, Lund CM, Lindberg H, Knudsen MB, Tolver A, Suetta C, Pappot H
Acta Oncol 2022 Sep;61(9):1036-1042. Epub 2022 Aug 25 doi: 10.1080/0284186X.2022.2114378. PMID: 36017555
Comparative Effectiveness of Immune Checkpoint Inhibitors in Patients with Platinum Refractory Advanced Urothelial Carcinoma.
Swami U, Haaland B, Kessel A, Nussenzveig R, Maughan BL, Esther J, Sirohi D, Pal SK, Grivas P, Agarwal N
J Urol 2021 Mar;205(3):709-717. Epub 2020 Oct 20 doi: 10.1097/JU.0000000000001412. PMID: 33080152
A rare bladder cancer--small cell carcinoma: review and update.
Ismaili N
Orphanet J Rare Dis 2011 Nov 13;6:75. doi: 10.1186/1750-1172-6-75. PMID: 22078012Free PMC Article

Therapy

Nivolumab plus Gemcitabine-Cisplatin in Advanced Urothelial Carcinoma.
van der Heijden MS, Sonpavde G, Powles T, Necchi A, Burotto M, Schenker M, Sade JP, Bamias A, Beuzeboc P, Bedke J, Oldenburg J, Chatta G, Ürün Y, Ye D, He Z, Valderrama BP, Ku JH, Tomita Y, Filian J, Wang L, Purcea D, Patel MY, Nasroulah F, Galsky MD; CheckMate 901 Trial Investigators
N Engl J Med 2023 Nov 9;389(19):1778-1789. Epub 2023 Oct 22 doi: 10.1056/NEJMoa2309863. PMID: 37870949
Avelumab First-line Maintenance Therapy for Advanced Urothelial Carcinoma: Comprehensive Clinical Subgroup Analyses from the JAVELIN Bladder 100 Phase 3 Trial.
Grivas P, Park SH, Voog E, Caserta C, Gurney H, Bellmunt J, Kalofonos H, Ullén A, Loriot Y, Sridhar SS, Yamamoto Y, Petrylak DP, Sternberg CN, Gupta S, Huang B, Costa N, Laliberte RJ, di Pietro A, Valderrama BP, Powles T
Eur Urol 2023 Jul;84(1):95-108. Epub 2023 Apr 28 doi: 10.1016/j.eururo.2023.03.030. PMID: 37121850
Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study.
Siefker-Radtke AO, Necchi A, Park SH, García-Donas J, Huddart RA, Burgess EF, Fleming MT, Rezazadeh Kalebasty A, Mellado B, Varlamov S, Joshi M, Duran I, Tagawa ST, Zakharia Y, Akapame S, Santiago-Walker AE, Monga M, O'Hagan A, Loriot Y; BLC2001 Study Group
Lancet Oncol 2022 Feb;23(2):248-258. Epub 2022 Jan 11 doi: 10.1016/S1470-2045(21)00660-4. PMID: 35030333
Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial.
Powles T, Csőszi T, Özgüroğlu M, Matsubara N, Géczi L, Cheng SY, Fradet Y, Oudard S, Vulsteke C, Morales Barrera R, Fléchon A, Gunduz S, Loriot Y, Rodriguez-Vida A, Mamtani R, Yu EY, Nam K, Imai K, Homet Moreno B, Alva A; KEYNOTE-361 Investigators
Lancet Oncol 2021 Jul;22(7):931-945. Epub 2021 May 26 doi: 10.1016/S1470-2045(21)00152-2. PMID: 34051178
Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma.
Powles T, Park SH, Voog E, Caserta C, Valderrama BP, Gurney H, Kalofonos H, Radulović S, Demey W, Ullén A, Loriot Y, Sridhar SS, Tsuchiya N, Kopyltsov E, Sternberg CN, Bellmunt J, Aragon-Ching JB, Petrylak DP, Laliberte R, Wang J, Huang B, Davis C, Fowst C, Costa N, Blake-Haskins JA, di Pietro A, Grivas P
N Engl J Med 2020 Sep 24;383(13):1218-1230. Epub 2020 Sep 18 doi: 10.1056/NEJMoa2002788. PMID: 32945632

Prognosis

Real-world outcomes of first-line chemotherapy for unresectable stage III and IV bladder cancer.
Reesink DJ, van Melick HHE, van der Nat PB, Los M, Horenblas S, van de Garde EMW; Santeon MIBC Study Group
World J Urol 2023 Jun;41(6):1551-1562. Epub 2023 May 5 doi: 10.1007/s00345-023-04408-w. PMID: 37145158
Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study.
Siefker-Radtke AO, Necchi A, Park SH, García-Donas J, Huddart RA, Burgess EF, Fleming MT, Rezazadeh Kalebasty A, Mellado B, Varlamov S, Joshi M, Duran I, Tagawa ST, Zakharia Y, Akapame S, Santiago-Walker AE, Monga M, O'Hagan A, Loriot Y; BLC2001 Study Group
Lancet Oncol 2022 Feb;23(2):248-258. Epub 2022 Jan 11 doi: 10.1016/S1470-2045(21)00660-4. PMID: 35030333
Natural history, response to systemic therapy, and genomic landscape of plasmacytoid urothelial carcinoma.
Teo MY, Al-Ahmadie H, Seier K, Tully C, Regazzi AM, Pietzak E, Solit DB, Tickoo S, Reuter V, Cha EK, Herr H, Donahue T, Donat SM, Dalbagni G, Bochner BH, Funt S, Iyer GV, Bajorin DF, Ostrovnaya I, Rosenberg JE
Br J Cancer 2021 Mar;124(7):1214-1221. Epub 2021 Jan 21 doi: 10.1038/s41416-020-01244-2. PMID: 33473164Free PMC Article
Immune checkpoint inhibitors for metastatic bladder cancer.
Massari F, Di Nunno V, Cubelli M, Santoni M, Fiorentino M, Montironi R, Cheng L, Lopez-Beltran A, Battelli N, Ardizzoni A
Cancer Treat Rev 2018 Mar;64:11-20. Epub 2018 Jan 31 doi: 10.1016/j.ctrv.2017.12.007. PMID: 29407369
A rare bladder cancer--small cell carcinoma: review and update.
Ismaili N
Orphanet J Rare Dis 2011 Nov 13;6:75. doi: 10.1186/1750-1172-6-75. PMID: 22078012Free PMC Article

Clinical prediction guides

Safety and effectiveness of pembrolizumab monotherapy in Japanese patients with unresectable urothelial carcinoma: a nation-wide post-marketing surveillance.
Nishiyama H, Tanaka Y, Hamada M, Ozaki M, Minegishi T, Ito Y, Maekawa S, Yamamoto N
BMC Cancer 2023 Jun 20;23(1):565. doi: 10.1186/s12885-023-10930-2. PMID: 37340317Free PMC Article
Avelumab First-line Maintenance Therapy for Advanced Urothelial Carcinoma: Comprehensive Clinical Subgroup Analyses from the JAVELIN Bladder 100 Phase 3 Trial.
Grivas P, Park SH, Voog E, Caserta C, Gurney H, Bellmunt J, Kalofonos H, Ullén A, Loriot Y, Sridhar SS, Yamamoto Y, Petrylak DP, Sternberg CN, Gupta S, Huang B, Costa N, Laliberte RJ, di Pietro A, Valderrama BP, Powles T
Eur Urol 2023 Jul;84(1):95-108. Epub 2023 Apr 28 doi: 10.1016/j.eururo.2023.03.030. PMID: 37121850
Tailored immunotherapy approach with nivolumab with or without ipilimumab in patients with advanced transitional cell carcinoma after platinum-based chemotherapy (TITAN-TCC): a multicentre, single-arm, phase 2 trial.
Grimm MO, Grün CB, Niegisch G, Pichler M, Roghmann F, Schmitz-Dräger B, Baretton G, Schmitz M, Bolenz C, Foller S, Leucht K, Schumacher U, Schostak M, Meran J, Loidl W, Zengerling F
Lancet Oncol 2023 Apr;24(4):347-359. Epub 2023 Feb 28 doi: 10.1016/S1470-2045(23)00053-0. PMID: 36868252
Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial.
Powles T, Csőszi T, Özgüroğlu M, Matsubara N, Géczi L, Cheng SY, Fradet Y, Oudard S, Vulsteke C, Morales Barrera R, Fléchon A, Gunduz S, Loriot Y, Rodriguez-Vida A, Mamtani R, Yu EY, Nam K, Imai K, Homet Moreno B, Alva A; KEYNOTE-361 Investigators
Lancet Oncol 2021 Jul;22(7):931-945. Epub 2021 May 26 doi: 10.1016/S1470-2045(21)00152-2. PMID: 34051178
Immune checkpoint inhibitors for metastatic bladder cancer.
Massari F, Di Nunno V, Cubelli M, Santoni M, Fiorentino M, Montironi R, Cheng L, Lopez-Beltran A, Battelli N, Ardizzoni A
Cancer Treat Rev 2018 Mar;64:11-20. Epub 2018 Jan 31 doi: 10.1016/j.ctrv.2017.12.007. PMID: 29407369

Recent systematic reviews

Clinical evidence for the first-line treatment of advanced urothelial carcinoma: Current paradigms and emerging treatment options.
Koufopoulou M, Miranda PAP, Kazmierska P, Deshpande S, Gaitonde P
Cancer Treat Rev 2020 Sep;89:102072. Epub 2020 Jul 22 doi: 10.1016/j.ctrv.2020.102072. PMID: 32769039
Gemcitabine for unresectable, locally advanced or metastatic bladder cancer.
Shelley M, Cleves A, Wilt TJ, Mason M
Cochrane Database Syst Rev 2011 Apr 13;(4):CD008976. doi: 10.1002/14651858.CD008976.pub2. PMID: 21491413

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...